the involvement of kras gene 3'-utr polymorphisms in risk of cancer and influence on patient response to anti-egfr therapy in metastatic colorectal cancer: a meta-analysis
Clicks: 212
ID: 205479
2014
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
212 views
51 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #100 of 171 articles by views in jurnal tam
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 171 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Hou-Qun Ying,1,2 Feng Wang,2 Bang-Shun He,2 Yu-Qin Pan,2 Tian-Yi Gao,2 Ye-Qiong Xu,2 Rui Li,2 Qi-Wen Deng,2 Hui-Lin Sun,2 Shu-Kui Wang21Medical College, Southeast University, Nanjing, Jiangsu, People's Republic of China; 2Central Laboratory, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, People's Republic of ChinaBackground: Genetic variation of the Kras oncogene is a candidate factor for increasing susceptibility to carcinoma and modulating response of metastatic colorectal cancer (mCRC) patients treated with anti-epidermal growth factor receptor monoclonal antibody (anti-EGFR). However, results from an increasing number of studies concerning the association of Kras gene rs712 and rs61764370 polymorphisms with risk of cancer and treatment of mCRC using anti-EGFR remain equivocal.Methods: Risk associations were evaluated in 1,661 cases and 2,139 controls from six studies concerning rs712 and 14,796 cases and 14,985 controls from 29 studies concerning rs61764370. Response association was also examined in a subset of four studies pertaining to rs61764370 and anti-EGFR treatment in mCRC.Results: Results of a meta-analysis showed that allele T (P-value of heterogeneity test [PH] =0.08, odds ratio [OR] =1.33, 95% confidence interval [CI]: 1.08–1.64) and genotype GT/TT (PH=0.14, OR =1.30, 95% CI: 1.10–1.55) in rs712 were strongly associated with cancer in Chinese subjects. No evidence of association was observed between rs712 and risk of cancer in the overall population or between rs61764370 and ovarian, breast, colorectal, or non-small-cell lung cancer risk in the Caucasian population. No significant association was found between rs61764370 and patient response to anti-EGFR therapy in mCRC.Conclusion: The findings not only provide further evidence that allele T of rs712 increases genetic predisposition to cancer in Chinese population, but also no significant association between rs61764370 and cancer risk in Caucasian population, and suggest that genotype GT/TT of rs61764370 may not be a biomarker for predicting clinical outcome of anti-EGFR therapy in mCRC.Keywords: rs712, rs61764370, single nuclear polymorphism
| Reference Key |
hq2014oncotargetsthe
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Ying HQ;Wang F;He BS;Pan YQ;Gao TY;Xu YQ;Li R;Deng QW;Sun HL;Wang SK |
| Journal | jurnal tam |
| Year | 2014 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.